Keywords: Novartis, Imatinib, PAH, Pulmonary arterial hypertension, ERS Congress, Actelion, Tracleer

Novartis cancer drug imatinib shows efficacy in PAH

Article | 26 September 2011

Print This

Swiss drug major Novartis (NOVN: VX) yesterday announced new data today at the European Respiratory Society (ERS) congress on the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in